197 related articles for article (PubMed ID: 33440396)
1. Combination of CA19-9 and Blood Free-Circulating Methylated RUNX3 May Be Useful to Diagnose Stage I Pancreatic Cancer.
Fujimoto Y; Suehiro Y; Kaino S; Suenaga S; Tsuyama T; Matsui H; Higaki S; Fujii I; Suzuki C; Hoshida T; Matsumoto T; Takami T; Nagano H; Sakaida I; Yamasaki T
Oncology; 2021; 99(4):234-239. PubMed ID: 33440396
[TBL] [Abstract][Full Text] [Related]
2. Blood Free-Circulating DNA Testing of Methylated RUNX3 Is Useful for Diagnosing Early Gastric Cancer.
Hideura E; Suehiro Y; Nishikawa J; Shuto T; Fujimura H; Ito S; Goto A; Hamabe K; Saeki I; Okamoto T; Higaki S; Fujii I; Suzuki C; Hoshida T; Matsumoto T; Takami T; Sakaida I; Yamasaki T
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32224873
[TBL] [Abstract][Full Text] [Related]
3. CA19-9 in Combination with Methylated HOXA1 and SST Is Useful to Diagnose Stage I Pancreatic Cancer.
Suehiro Y; Suenaga S; Kunimune Y; Yada S; Hamamoto K; Tsuyama T; Amano S; Matsui H; Higaki S; Fujii I; Suzuki C; Hoshida T; Matsumoto T; Fujimoto Y; Kaino S; Shinjo K; Kondo Y; Sakaida I; Takami T; Nagano H; Yamasaki T
Oncology; 2022; 100(12):674-684. PubMed ID: 36244341
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of tumor-derived methylated RUNX3 sequences in the serum of gastric cancer patients.
Sakakura C; Hamada T; Miyagawa K; Nishio M; Miyashita A; Nagata H; Ida H; Yazumi S; Otsuji E; Chiba T; Ito K; Ito Y
Anticancer Res; 2009 Jul; 29(7):2619-25. PubMed ID: 19596937
[TBL] [Abstract][Full Text] [Related]
5. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
[TBL] [Abstract][Full Text] [Related]
6. Circulating methylated RUNX3 and SFRP1 genes as a noninvasive panel for early detection of colorectal cancer.
Pasha HF; Radwan MI; Yehia AM; Toam MM
Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1342-1349. PubMed ID: 31524773
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the RUNX3 gene methylation in serum DNA from esophagus squamous cell carcinoma, gastric and colorectal adenocarcinoma patients.
Zheng Y; Zhang Y; Huang X; Chen L
Hepatogastroenterology; 2011; 58(112):2007-11. PubMed ID: 22234069
[TBL] [Abstract][Full Text] [Related]
8. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
9. Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer.
Banfi G; Zerbi A; Pastori S; Parolini D; Di Carlo V; Bonini P
Clin Chem; 1993 Mar; 39(3):420-3. PubMed ID: 8448851
[TBL] [Abstract][Full Text] [Related]
10. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter.
Luo G; Jin K; Deng S; Cheng H; Fan Z; Gong Y; Qian Y; Huang Q; Ni Q; Liu C; Yu X
Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188409. PubMed ID: 32827580
[TBL] [Abstract][Full Text] [Related]
11. Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease.
Ritts RE; Nagorney DM; Jacobsen DJ; Talbot RW; Zurawski VR
Pancreas; 1994 Nov; 9(6):707-16. PubMed ID: 7846013
[TBL] [Abstract][Full Text] [Related]
12. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9.
Majumder S; Taylor WR; Foote PH; Berger CK; Wu CW; Mahoney DW; Bamlet WR; Burger KN; Postier N; de la Fuente J; Doering KA; Lidgard GP; Allawi HT; Petersen GM; Chari ST; Ahlquist DA; Kisiel JB
Clin Cancer Res; 2021 May; 27(9):2523-2532. PubMed ID: 33593879
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.
Kawa S; Tokoo M; Hasebe O; Hayashi K; Imai H; Oguchi H; Kiyosawa K; Furuta S; Homma T
Br J Cancer; 1994 Sep; 70(3):481-6. PubMed ID: 8080734
[TBL] [Abstract][Full Text] [Related]
14. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
15. RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker.
Nishio M; Sakakura C; Nagata T; Komiyama S; Miyashita A; Hamada T; Kuryu Y; Ikoma H; Kubota T; Kimura A; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Kokuba Y; Sonoyama T; Ida H; Ito K; Chiba T; Ito Y; Otsuji E
Anticancer Res; 2010 Jul; 30(7):2673-82. PubMed ID: 20682997
[TBL] [Abstract][Full Text] [Related]
16. Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer.
Jiang JT; Wu CP; Deng HF; Lu MY; Wu J; Zhang HY; Sun WH; Ji M
World J Gastroenterol; 2004 Jun; 10(11):1675-7. PubMed ID: 15162550
[TBL] [Abstract][Full Text] [Related]
17. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
18. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.
Staal B; Liu Y; Barnett D; Hsueh P; He Z; Gao C; Partyka K; Hurd MW; Singhi AD; Drake RR; Huang Y; Maitra A; Brand RE; Haab BB
Clin Cancer Res; 2019 May; 25(9):2745-2754. PubMed ID: 30617132
[TBL] [Abstract][Full Text] [Related]
19. Tumor-associated trypsin inhibitor in pancreatic diseases.
Aroasio E; Piantino P
Scand J Clin Lab Invest Suppl; 1991; 207():71-3. PubMed ID: 1723534
[TBL] [Abstract][Full Text] [Related]
20. Combined detection of CA19-9 and B7-H4 in the diagnosis and prognosis of pancreatic cancer.
Xu X; Xiao Y; Hong B; Hao B; Qian Y
Cancer Biomark; 2019; 25(3):251-257. PubMed ID: 31282407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
